Teva Pharmaceutical Industries Limited (TEVA)
Market Cap | 19.60B |
Revenue (ttm) | 16.62B |
Net Income (ttm) | -1.29B |
Shares Out | 1.15B |
EPS (ttm) | -1.14 |
PE Ratio | n/a |
Forward PE | 6.64 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 9,508,516 |
Open | 17.22 |
Previous Close | 16.97 |
Day's Range | 16.97 - 17.31 |
52-Week Range | 12.47 - 22.80 |
Beta | 0.61 |
Analysts | Strong Buy |
Price Target | 25.00 (+46.28%) |
Earnings Date | Jul 30, 2025 |
About TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
Financial Performance
In 2024, Teva Pharmaceutical's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for TEVA stock is "Strong Buy." The 12-month stock price forecast is $25.0, which is an increase of 46.28% from the latest price.
News

Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine
TEL AVIV, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the final analysis of the pan-European PEARL Phase 4 migraine prevent...

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established with ...

Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ET Company Participants Richard D. Francis - President, CEO & Director ...

Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies Global Healthcare Conference Transcript
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Jefferies Global Healthcare Conference June 4, 2025 9:20 AM ET Company Participants Christine Fox - Executive VP of U.S. Commercial Business Eric A....

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the pricing and early acceptance results of its previously announ...

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection with its previously announ...

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
PARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results fro...

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date
PARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the present...

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
TEL AVIV, Israel and PARSIPPANY, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), is hosting today a 2025 Innovation & Strategy Day, to launch the acce...

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibody Designation underscores the potential of TEV-53408, currently undergoing a Phase 2a study for the treatment of celi...

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that members of its executive management team will present at two upcoming ...

Why Is Teva Stock Trading Higher On Tuesday?
Teva Pharmaceutical Industries Ltd TEVA and Biolojic Design Ltd announced that Teva initiated IND-enabling studies with BD9, a dual-specific multibody targeting both TSLP (Thymic stromal lymphopoietin...

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
REHOVOT, Israel and WASHINGTON and TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) and Biolojic Design Ltd. (“Biolojic”), a biotechnology c...

Why Investors Should Watch Teva Despite Regional Risks
Despite the lack of cautious enthusiasm from retail investors in Teva, it continues to beat consensus estimates by wide margins and has once again raised its 2025 financial guidance. I highlight Auste...

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it is increasing the maximum tender amount of its tender offe...

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully upsized its offering and priced approximately...

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to BB...

Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it has commenced tender offers (the “Offers”) to purchase for...

Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue $2,000,000,000 (equivalent) of senior notes...

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Moody's Investor Services (“Moody's”) has raised the company's corporate credit ratin...

Teva's Transformation: Why This 'Forgotten Pharma' Could Deliver 30% Upside
Teva's betting big on biosimilars and specialty drugs, with AUSTEDO and UZEDY leading the charge. Management's $700 million cost-cutting plan is on track, aiming for a 30% operating margin by 2027. Re...

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says
The drugmaker reported first-quarter earnings that beat expectations and raised its full-year guidance.

Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum
Teva Pharmaceutical Industries Ltd TEVA stock is trading higher on Wednesday after the company's first-quarter 2025 financial results. Here are the details.
Teva CEO Richard Francis on tariffs: Well positioned to maintain guidance despite duties
Richard Francis, Teva Pharma CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, any pharma shortages in the U.S., and much more.

Teva Pharmaceutical Industries Limited (TEVA) Q1 2025 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2025 Earnings Call May 7, 2025 8:00 AM ET Company Participants Christopher Stevo - SVP, IR Richard Francis - President & CEO Eric A. Hughes - EVP...